MussoGGambinoRBoS. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment panel III criteria in nonobese nondiabetic. Diabetes Care. 2008;31
(3):562–568.
4.
AhmedMHBarakatSAlmobarakAO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?J Obes. 2012;2012:483135. doi:10.1155/2012/483135.
5.
MonsourHPJrFrenetteCTWyneK. Fatty liver: a link to cardiovascular disease—its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J. 2012;8
(3):21–25.
6.
BreaAMosqueraDMartínEAriztiACorderoJLRosE. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25
(5):1045–1050.
7.
TargherGBertoliniLPoliF. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54
(12):3541–3546.
8.
NikolicDKatsikiNMontaltoGIsenovicERMikhailidisDPRizzoM. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013;5
(3):928–948.
9.
LuceroDZagoVLópezGI. Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?Clin Chim Acta. 2011;412
(7-8):587–592.
10.
LuceroDZagoVLópezGH. Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography. Clin Biochem. 2012;45
(4-5):293–297.
11.
ZagoVGorzalczanySLuceroDTairaCSchreierL. Role of HDL in neutralizing the VLDL effect on endothelial dysfunction. Microvasc Res. 2013;89:153–158.
12.
RizzoMTaylorJMBarbagalloCMBerneisKKBlanchePJKraussRM. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2004;24
(1):141–146.
13.
MiksztowiczVLuceroDZagoV. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev. 2012;28
(6):535–541.
14.
RizzoMRiniGBBerneisK. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes. 2007;115
(8):477–482.
15.
RizzoMMikhailidisDP. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des. 2011;17
(33):3608–3610.
16.
RizzoMPerniceVFrasheriABerneisK. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis. 2008;197
(1):237–241.
17.
MikhailidisDPElisafMSRizzoM. “European Panel on Low Density Lipoprotein (LDL) Subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9
(5):533–571.
18.
Cortez-PintoHde MouraMCDayCP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 2006;44
(1):197–208.
19.
LuceroDZagoVLópezGI. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta. 2011;412
(1-2):143–147.
20.
RossR. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138
(5 Pt 2):S419–S420.
21.
CorradoERizzoMCoppolaGMuratoriICarellaMNovoS. Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study. Coron Artery Dis. 2008;19
(3):139–144.
22.
SookoianSPirolaCJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49
(4):600–607.
23.
PetersSAden RuijterHMBotsML. Attenuation of rate of change in carotid intima–media thickness by lipid-modifying drugs: impact on clinical outcomes. Am J Cardiovasc Drugs. 2011;11
(4):253–263.
24.
AthyrosVGTziomalosKGossiosTD; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376
(9756):1916–1922.
25.
TikkanenMJFayyadRFaergemanO; IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013;168
(4):3846–3852.
26.
LiaoHLiZZhengD. Increased Hs-CRP/adiponectin ratio is associated with increase carotid intima–media thickness. Lipids Health Dis. 2014;13:120.
BergGMiksztowiczVSchreierL. Metalloproteinases in metabolic syndrome. Clin Chim Acta. 2011;412
(19-20):1731–1739.
29.
TanCLiuYLiW. Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima–media thickness. Atherosclerosis. 2014;232
(1):199–203.
30.
MoonSHNohTSChoYS. Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography. Angiology. 2015;66
(5):472–480.
